Virological Suppression and Its Associated Factors of Dolutegravir Based Regimen in a Resource-Limited Setting: An Observational Retrospective Study in Ethiopia

References

• Cohen MS, Chen YQ, McCauley M, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011;365(6):493–505. doi:10.1056/NEJMoa1105243
   PubMed Web of Science ®Google Scholar
• Oguntibeju OO. Quality of life of people living with HIV and AIDS and antiretroviral therapy. HIV/AIDS. 2012;4:117.
   Google Scholar
• Organization WH.. Updated Recommendations on First-Line and Second-Line Antiretroviral Regimens and Post-Exposure Prophylaxis and Recommendations on Early Infant Diagnosis of HIV: Interim Guidelines: Supplement to the 2016 Consolidated Guidelines on the Use of Antiretroviral Drugs for Treating and Preventing HIV Infection. World Health Organization; 2018.
   Google Scholar
• Walmsley SL, Antela A, Clumeck N, et al. Dolutegravir plus abacavir–lamivudine for the treatment of HIV-1 infection. N Engl J Med. 2013;369(19):1807–1818. doi:10.1056/NEJMoa1215541
   PubMed Web of Science ®Google Scholar
• Oliveira M, Mesplede T, Quashie PK, Moïsi D, Wainberg MA. Resistance mutations against dolutegravir in HIV integrase impair the emergence of resistance against reverse transcriptase inhibitors. AIDS. 2014;28(6):813–819. doi:10.1097/QAD.0000000000000199
   PubMed Web of Science ®Google Scholar
• Treviño A, Cabezas T, Lozano AB, et al. Dolutegravir for the treatment of HIV-2 infection. J Clin Virol. 2015;64:12–15. doi:10.1016/j.jcv.2015.01.001
   Web of Science ®Google Scholar
• Cahn P, Pozniak AL, Mingrone H, et al. Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study. Lancet. 2013;382(9893):700–708. doi:10.1016/S0140-6736(13)61221-0
   PubMed Web of Science ®Google Scholar
• Trottier B, Lake JE, Logue K, et al. Dolutegravir/abacavir/lamivudine versus current ART in virally suppressed patients (STRIIVING): a 48-week, randomized, non-inferiority, open-label, phase IIIb study. Antivir Ther. 2017;22(4):295–305. doi:10.3851/IMP3166
   PubMed Web of Science ®Google Scholar
• Snedecor SJ, Radford M, Kratochvil D, Grove R, Punekar YS. Comparative efficacy and safety of dolutegravir relative to common core agents in treatment-naïve patients infected with HIV-1: a systematic review and network meta-analysis. BMC Infect Dis. 2019;19(1):484. doi:10.1186/s12879-019-3975-6
   PubMed Web of Science ®Google Scholar
• Cruciani M, Parisi SG. Dolutegravir based antiretroviral therapy compared to other combined antiretroviral regimens for the treatment of HIV-infected naive patients: a systematic review and meta-analysis. PLoS One. 2019;14(9):e0222229. doi:10.1371/journal.pone.0222229
   PubMed Web of Science ®Google Scholar
• McCormack PL. Dolutegravir: a review of its use in the management of HIV-1 infection in adolescents and adults. Drugs. 2014;74(11):1241–1252. doi:10.1007/s40265-014-0256-y
   PubMed Web of Science ®Google Scholar
• HIV W. AIDS. Monitoring Response to ART and Diagnosis of Treatment Failure. 2013 ed. June, 2013.
   Google Scholar
• Organization WH. Adherence to Long-Term Therapies: Evidence for Action. World Health Organization; 2003.
   Google Scholar
• Sangeda RZ, Mosha F, Prosperi M, et al. Pharmacy refill adherence outperforms self-reported methods in predicting HIV therapy outcome in resource-limited settings. BMC Public Health. 2014;14(1):1035. doi:10.1186/1471-2458-14-1035
   PubMed Web of Science ®Google Scholar
• Evaluation FD. Human Immunodeficiency Virus-1 Infection: Developing Antiretroviral drugs for Treatment. Guidance for industry; 2015.
   Google Scholar
• O’brien RM. A caution regarding rules of thumb for variance inflation factors. Qual Quant. 2007;41(5):673–690. doi:10.1007/s11135-006-9018-6
   Web of Science ®Google Scholar
• Hosmer DW Jr, Lemeshow S, Sturdivant RX. Applied Logistic Regression. Vol. 398. John Wiley & Sons; 2013.
   Google Scholar
• Nabitaka VM, Nawaggi P, Campbell J, et al. High acceptability and viral suppression of patients on dolutegravir-based first-line regimens in pilot sites in Uganda: a mixed-methods prospective cohort study. PLoS One. 2020;15(5):e0232419. doi:10.1371/journal.pone.0232419
   PubMed Web of Science ®Google Scholar
• Group NAS. Dolutegravir-based or low-dose efavirenz–based regimen for the treatment of HIV-1. N Engl J Med. 2019;381(9):816–826. doi:10.1056/NEJMoa1904340
   Web of Science ®Google Scholar
• Venter W, Moorhouse M, Sokhela S, et al. The ADVANCE trial: phase 3, randomized comparison of TAF/FTC/DTG, TDF/FTC/DTG or TDF/FTC/EFV for first-line treatment of HIV-1 infection. Paper presented at: Journal of the International Aids Society; 2019.
   Google Scholar
• Norwood J, Turner M, Bofill C, et al. Weight gain in persons with HIV switched from efavirenz-based to integrase strand transfer inhibitor-based regimens. J Acquir Immune Defic Syndr. 2017;76(5):527. doi:10.1097/QAI.0000000000001525
   PubMed Web of Science ®Google Scholar
• Bourgi K, Rebeiro PF, Turner M, et al. Greater weight gain in treatment-naive persons starting dolutegravir-based antiretroviral therapy. Clin Infect Dis. 2020;70(7):1267–1274. doi:10.1093/cid/ciz407
   PubMed Web of Science ®Google Scholar
• Rizzardo S, Lanzafame M, Lattuada E, et al. Dolutegravir monotherapy and body weight gain in antiretroviral naive patients. AIDS. 2019;33(10):1673–1674. doi:10.1097/QAD.0000000000002245
   PubMed Web of Science ®Google Scholar
• Wohl DA, Yazdanpanah Y, Baumgarten A, et al. Bictegravir combined with emtricitabine and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial. Lancet HIV. 2019;6(6):e355–e363. doi:10.1016/S2352-3018(19)30077-3
   PubMed Web of Science ®Google Scholar
• Burns JE, Stirrup OT, Dunn D, et al. No overall change in the rate of weight gain after switching to an integrase-inhibitor in virologically suppressed adults with HIV. AIDS. 2020;34(1):109–114. doi:10.1097/QAD.0000000000002379
   PubMed Web of Science ®Google Scholar
• Blair SN, Church TS. The fitness, obesity, and health equation: is physical activity the common denominator? JAMA. 2004;292(10):1232–1234. doi:10.1001/jama.292.10.1232
   PubMed Web of Science ®Google Scholar
• Bodnar LM, Siega-Riz AM, Simhan HN, Himes KP, Abrams B. Severe obesity, gestational weight gain, and adverse birth outcomes. Am J Clin Nutr. 2010;91(6):1642–1648. doi:10.3945/ajcn.2009.29008
   PubMed Web of Science ®Google Scholar
• Desta AA, Woldearegay TW, Futwi N, et al. HIV virological non-suppression and factors associated with non-suppression among adolescents and adults on antiretroviral therapy in northern Ethiopia: a retrospective study. BMC Infect Dis. 2020;20(1):1–10. doi:10.1186/s12879-019-4732-6
   Web of Science ®Google Scholar
• Bayu B, Tariku A, Bulti AB, Habitu YA, Derso T, Teshome DF. Determinants of virological failure among patients on highly active antiretroviral therapy in University of Gondar Referral Hospital, Northwest Ethiopia: a case–control study. HIV/AIDS. 2017;9:153.
   Google Scholar
• Maina E, Mureithi H, Adan A, Muriuki J, Lwembe R, Bukusi E. Incidences and factors associated with viral suppression or rebound among HIV patients on combination antiretroviral therapy from three counties in Kenya. Int J Infect Dis. 2020. doi:10.1016/j.ijid.2020.05.097
   Web of Science ®Google Scholar
• Kiweewa F, Esber A, Musingye E, et al. HIV virologic failure and its predictors among HIV-infected adults on antiretroviral therapy in the African Cohort Study. PLoS One. 2019;14(2):e0211344. doi:10.1371/journal.pone.0211344
   PubMed Web of Science ®Google Scholar
• Casado JL, Sabido R, Perez-Elías MJ, et al. Percentage of adherence correlates with the risk of protease inhibitor (PI) treatment failure in HIV-infected patients. Antivir Ther. 1999;4:157–162.
   PubMed Web of Science ®Google Scholar
• Omooja J, Nannyonjo M, Sanyu G, et al. Rates of HIV-1 virological suppression and patterns of acquired drug resistance among fisherfolk on first-line antiretroviral therapy in Uganda. J Antimicrob Chemother. 2019;74(10):3021–3029. doi:10.1093/jac/dkz261
   Web of Science ®Google Scholar
• Hanna DB, Felsen UR, Ginsberg MS, et al. Increased antiretroviral therapy use and virologic suppression in the bronx in the context of multiple HIV prevention strategies. AIDS Res Hum Retroviruses. 2016;32(10–11):955–963. doi:10.1089/aid.2015.0345
   PubMed Web of Science ®Google Scholar
• Lokpo SY, Ofori-Attah PJ, Ameke LS, et al. Viral suppression and its associated factors in HIV patients on Highly Active Antiretroviral Therapy (HAART): a Retrospective Study in the Ho Municipality, Ghana. AIDS Res Treat. 2020;2020:1–7. doi:10.1155/2020/9247451
   Web of Science ®Google Scholar
• Resino S, Resino R, Micheloud D, et al. Long-term effects of highly active antiretroviral therapy in pretreated, vertically HIV type 1-infected children: 6 years of follow-up. Clin Infect Dis. 2006;42(6):862–869. doi:10.1086/500412
   Web of Science ®Google Scholar